145757-47-7
145757-47-7 structure
- Name: Carboxy-PTIO
- Chemical Name: 4-(1,3-dihydroxy-4,4,5,5-tetramethylimidazolidin-2-yl)benzoic acid
- CAS Number: 145757-47-7
- Molecular Formula: C14H17N2O4?
- Molecular Weight: 277.30
- Catalog: Signaling Pathways Immunology/Inflammation NO Synthase
- Create Date: 2017-06-05 16:33:23
- Modify Date: 2025-08-27 15:06:47
-
Carboxy-PTIO is a potent nitric oxide (NO) scavenger that can make a quick reaction with NO to produce NO2. Carboxy-PTIO can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model[1][2][3].
| Name | 4-(1,3-dihydroxy-4,4,5,5-tetramethylimidazolidin-2-yl)benzoic acid |
|---|
| Description | Carboxy-PTIO is a potent nitric oxide (NO) scavenger that can make a quick reaction with NO to produce NO2. Carboxy-PTIO can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Carboxy-PTIO (200 μM; 1 h prior to physalin A; 24 hours) significantly suppresses the stimulation of NO expression induced by physalin A treatment, but no change is observed in Carboxy-PTIO treatment alone[1]. Carboxy-PTIO (200 μM; 1 h prior to physalin A; 24 hours) reduces physalin A-induced cleavage of procaspase-3 and PARP, down-regulated ICAD expression,diminishing DNA fragmentation in nuclei[1]. Carboxy-PTIO (200 μM; 1 h prior to physalin A; 24 hours) shows no effect on iNOS expression. However, decreased-mTOR and p-mTOR levels induced by physalin A is reversed by Carboxy-PTIO with concomitant suppression of LC3 I to LC3 II conversions in A375-S2 cells[1]. Cell Viability Assay[1] Cell Line: A375-S2 cells Concentration: 200 μM Incubation Time: 1 h prior to physalin A; 24 hours Result: Diminished physalin A-induced procaspase-3 and PARP cleavage. |
| In Vivo | Carboxy-PTIO (intravenous injection; 0.056-1.70 mg/kg/min; infused for 1 hr beginning 90 min after the LPS injection 90 min) treatment improves the hypotension, renal dysfunction and survival rate in Lps-treated rats. But it does not affect each parameter in naomal rats[3]. Animal Model: SD rats[3] Dosage: 0.056-1.70 mg/kg/min Administration: Intravenous injection; 0.056-1.70 mg/kg/min; infused for 1 hr beginning 90 min after the LPS injection 90 min Result: Exhibited a potent therapeutic value in endotoxin shock through the direct scavenging action against NO. |
| References |
| Molecular Formula | C14H17N2O4? |
|---|---|
| Molecular Weight | 277.30 |
| Exact Mass | 277.11900 |
| PSA | 69.29000 |
| LogP | 1.75670 |